Marching to the tune of the groundswell generated by Western Covid-19 vaccines approved, distributed and administered in the US, UK and the EU in recent weeks, Chinese vaccine manufacturers have been beating the drum for their candidates in countries in Latin America and the Middle East as well as at home.
TechnipFMC has restarted plans to split into two publicly traded companies: TechnipFMC and Technip Energies. The group put the separation plans on hold last March because of the coronavirus pandemic and turbulent financial markets.
Shell Canada has signed a deal to invest in Varennes Carbon Recycling, the first waste-to-low-carbon fuels plant in Quebec. Shell will take a 40% interest in the plant, which will use technology developed by Canadian clean tech company Enerkem.
Baxter BioPharma Solutions has contracted to support production of US biotech Novavax’s new Covid-19 vaccine in Germany, when it is approved. Phase 3 data from late-stage trials is expected to be revealed soon.
Fujifilm Diosynth Biotechnologies, a subsidiary of Japan’s Fujifilm Corp., has announced plans to spend more than $2 billion to build a new large-scale cell culture production site in the US to accelerate the growth of its biopharma CDMO business.
Germany’s BioNTech has scaled up its projections for the number of doses of its Covid-19 vaccine it will make this year from 1.3 billion to 2 billion, as it seeks approvals from regulatory agencies outside the US, UK and the EU, where its Comirnaty-branded product is already on the market.
French pharma Sanofi is once again boosting its immunotherapy capabilities, this time with the acquisition of UK biotech Kymab. The company will make an upfront payment of about $1.1 billion plus up to $350 million upon Kymab achieving certain milestones.
Finland’s Neste has taken a minority stake in Alterra Energy as the two collaborate to develop and license the US company’s chemical recycling technology. The size of the stake and financial terms were not disclosed.
German pharmaceuticals, chemicals and life sciences group Merck has acquired compatriot CDMO AmpTec for an undisclosed sum. The deal is designed to strengthen its life sciences’ arm’s capabilities to develop and manufacture mRNA products for applications in vaccines, treatments and diagnostics for Covid-19, among other diseases.
The UK’s Medicines and Healthcare Products Regulatory Agency (MRHA) cleared US biotech Moderna’s mRNA-based Covid-19 vaccine for emergency use on Jan. 7, bringing the number of vaccines available in the country to three. At the same time, the British government ordered an additional 10 million doses, with a targeted supply of 17 million.
DuPont has started a share exchange offer as part of a Reverse Morris Trust transaction that will see it merge its Nutrition & Biosciences (N&B) business into International Flavors & Fragrances (IFF). The offer allows DuPont shareholders to swap all or part of their common stockholding for N&B shares, which will convert into IFF shares.
As it rolls out an increasing number of doses of its mRNA-based Covid-19 vaccine, US biotech Moderna has appointed a pharma industry veteran to spearhead the effort. Corinne Le Goff will take up the position on Jan. 19.
In its first deal of 2021, Azelis has purchased a majority shareholding in Vietnamese companies MKVN Chemicals and Viet Chemicals Trading and Service through their parent company Bellekimia Singapore. Financial terms were not disclosed.
Solvay’s transformation to a specialties company has taken another step forward with an agreement to sell its European and North American amphoteric surfactant business to US private equity firm OpenGate Capital.
CureVac has agreed a collaboration with Bayer to speed up production and distribution of its Covid-19 vaccine candidate CVnCOV, which began clinical trials in December with a goal of 36,500 participants in Europe and Asia.
PPG Industries has increased its offer for Tikkurila to €1.24 billion, or €27.75 per share, following the receipt of a rival bid for the Finnish paints company by an unnamed party. The transaction is expected to close this quarter, subject to the usual conditions. Financial terms were not disclosed.
Ineos completed its $5 billion acquisition of major petrochemicals assets from BP at the end of 2020, gaining 1,700 employees and adding two new subsidiaries, Ineos Aromatics and Ineos Acetyls.
Moderna’s mRNA-based Covid-19 vaccine will become the second to be administered in Europe. The European Commission granted a conditional marketing authorization to the US biotech on Jan. 6, shortly after the candidate was approved by the European Medicines Agency (EMA).
UK pharma services provider Ergomed is acquiring US contract research organization (CRO) MS Clinical Services, known as MedSource.
The UK’s Competition and Markets Authority (CMA) intends to open a Phase 2 investigation into Tronox’s proposed purchase of the TiZir titanium and iron business from French multinational mining and metallurgy group Eramet.
US nylon giant Ascend Performance Materials, which claims to be the world’s biggest fully integrated producer of polyamide 66 resin, has acquired Eurostar Engineering Plastics for an undisclosed sum. The French compounder manufactures a broad portfolio of flame-retardant engineered plastics and boasts expertise in halogen-free formulations.
Kemira and DuPont Nutrition and Biosciences have joined forces to develop and commercialize new, tailored biomaterials and bio-based chemicals based on DuPont’s biotechnology platform, which is at the advanced pilot stage and ready to be scaled up globally.
As the end of Donald Trump’s term as US president nears, environmental groups and even some career staffers within the Environmental Protection Agency (EPA) are scrambling to thwart last-minute efforts by the outgoing administration to cast in stone its rollback of Obama-era antipollution and safety legislation.
Through a subsidiary, Shanghai, China-based WuXi Biologics (WuXi Bio) is acquiring Bayer’s biologics substance plant at Wuppertal, Germany, for €150 million ($183.3 million).The transaction, expected to close in the first half of 2021, follows earlier Wuxi Bio purchases of plants the pharmaceuticals and agrochemicals group is shedding in Germany and the US.
German biopharmaceutical company Adrenomed has appointed Wolfgang Baiker as Chief Executive Officer (CEO), effective Jan. 1, 2021.
German oxo chemicals producer OQ Chemicals has announced plans to invest a “double-digit million euro” sum until the end of 2023 at its Oberhausen site as part of an efficiency drive.
Novozymes is to buy US-based Microbiome Labs, strengthening the Danish biotech’s presence in probiotics and gaining entry into the important North American market. The transaction is expected to close in the first half of January 2021.
Unsurprisingly in view of the surging cases of Covid-19 worldwide, there was little interruption in the flow of vaccine news – or at least talk about vaccines– during the Christmas and New Year break.
In another move to bolster its oncology portfolio, French pharma Servier has agreed to buy Agios Pharmaceuticals’ business, including its commercial, clinical and research-stage portfolio, for up to $2 billion. The transaction includes an upfront payment of $1.8 billion plus a potential $200 million in regulatory milestones and royalties.
German-headquartered multinational chemical distributor Brenntag has agreed to buy Canada’s Alpha Chemical for an undisclosed sum.
BASF has completed the first phase of an MDI expansion at its Geismar, Louisiana, complex in the US and taken an older MDI plant off stream. When the next phase is concluded, in the second half of 2021, the group’s MDI capacity by will rise by about a third.
Dutch renewables specialist Avantium has received a €5.4 million grant from the Netherlands Enterprise Agency to support expansion of the company’s furandicarboxylic acid (FDCA) pilot plant at Geleen, the Netherlands.
Eli Lilly is to buy Prevail Therapeutics, a US biotech focused on developing adeno-associated viral vector 9 (AAV9) gene therapies to treat neurodegenerative diseases, in a deal that could be worth as much as $1.04 billion.
Germany-based BioNTech and its Chinese partner Shanghai Fosun Pharmaceutical have agreed to provide an initial 100 million doses of the Mainz-headquartered company’s mRNA-based Covid-19 vaccine candidate to the People’s Republic of China in 2021, subject to regulatory approval. Initial supply will be from BioNTech’s production facilities in Germany.
The European Medicines Agency (EMA) on Dec. 21 provisionally cleared EU-wide use of the Pfizer-BioNTech Covid-19 vaccine, which will be marketed under the brand name Comirnaty. The Conditional Marketing Authorization paves the way for a rollout across the 27 member states, which is slated to begin by the end of the month and is expected to be a major logistics challenge.
